Nanomedicines accessible in the market for clinical interventions

Nanomedicines refers to nanotechnology inspired pharmaceutical products often referred to as 'nano-pharmaceuticals.' It has displayed commendable potential in enhancing therapeutic efficacy as well as in reducing the side effects associated with conventional drug counterpart. Recent years have monitored the entry of a large amount of nanomedicine in the market with an appreciable market share to date. Despite this, the development of nanomedicine is posing challenges (i.e., safety, regulatory hurdles, cost, scale-up issues, etc.) that need to be resolved for their market entry. This review presents a cross-sectional discussion on the nanomedicine-derived products available in the market for both clinical and diagnostic applications. An overview of its market potential, market size, and the products that are currently in the clinical stages is also provided. The review also expounds on the challenges faced by nano-drug products at the time of their commercialization.

Automated summary

Nanomedicines, also known as nano-pharmaceuticals, have shown great potential in improving therapeutic efficacy and reducing side effects. Despite a considerable market share, challenges such as safety, regulatory hurdles, and cost need to be addressed for their market entry. This review discusses the current market status, challenges, and potential of nanomedicines.